logo
  

Why Ocugen Is Rising In Pre-market?

Ocugen, Inc. (OCGN) said its partner, Bharat Biotech, posted positive results from a phase 2 analysis of the vaccine candidate, COVAXIN, in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv. The analysis showed that participants receiving a booster dose saw a significant increase in neutralizing titers. Additional data found that more than 75 percent of all participants had a detectible neutralizing antibody response six months post their second dose of COVAXIN. The booster dose analysis also found no serious adverse events, the company noted.

COVAXIN is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

Shares of Ocugen were up 6% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
RELATED NEWS
Follow RTT